Corbus Pharmaceuticals
Presence
Corbus Pharmaceuticals is a company listed under the stock ticker CRBP (US).
Executives
View the org chart displaying its 13 main executives
Most searched biographies at Corbus Pharmaceuticals
- Yuval Cohen, Chief Executive Officer and Director
- Alan Holmer, Chairman of the Board
- Yong Ben, Director
Popular executive movements at Corbus Pharmaceuticals
- Dominic Smethurst has joined the company as Chief Medical Officer (posted on March 1 2024).
Create your alert
to follow the executive moves at Corbus Pharmaceuticals.
Pharmaceuticals
Corbus Pharmaceuticals has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Corbus Pharmaceuticals
- Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
- Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
- Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
- Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
- Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
- Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Corbus Pharmaceuticals Announces Proposed Public Offering
- Corbus Pharmaceuticals Announces Pricing of Public Offering
- Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
- CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
- View more press releases Close
Social media about Corbus Pharmaceuticals
- Corbus Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Corbus Pharmaceuticals on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Yuval Cohen 
Call Corbus Pharmaceuticals at +1 617...
